Molluscum Contagiosum Clinical Trial
Official title:
Comparison of 10% Potassium Hydroxide Solution Versus Cryotherapy in the Treatment of Molluscum Contagiosum
Verified date | May 2023 |
Source | Combined Military Hospital Abbottabad |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A total of sixty patients presented to the outpatient dermatology department of Combined military hospital (CMH) Abbottabad with signs of molluscum contagiosum clinically diagnosed meeting inclusion criteria were enrolled. Sample size was calculated using WHO sample size calculator. They were divided into two groups i.e Group A and Group B using lottery method. Patients in Group A were subjected to cryotherapy (liquid nitrogen gas) whereas patients in Group B patients were subjected to 10% potassium hydroxide solution for 3 weeks and were followed up at 2nd, 4th, 8th and 12th week for observing the progress of therapy in both groups on each follow up visit and ascertaining the efficacy respectively.
Status | Completed |
Enrollment | 60 |
Est. completion date | April 30, 2023 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years to 12 Years |
Eligibility | Inclusion Criteria: - clinical diagnosis of molluscum contagiosum having 3-20 lesion - no history of treatment before - willingness to participate (given by parents) Exclusion Criteria: - Patients with facial lesions - known immunodeficiency - tendency for hypertrophic scarring - known hypersensitivity |
Country | Name | City | State |
---|---|---|---|
Pakistan | CMH Abbottabad | Abbottabad | Khyber Pakhtunkhwa |
Lead Sponsor | Collaborator |
---|---|
Combined Military Hospital Abbottabad |
Pakistan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy was assessed at 12th week by the clearance of lesion or not | Final evaluation in terms of efficacy was done at the follow up visit in 12th week and the method was termed as effective (Yes) on achieving complete clearance of lesions confirmed on clinical & physical examination of the affected areas by a consultant dermatologist using dermoscopy showing complete resolution of lesions. However, if lesions were not completely cleared at the end of 12th week, the treatment method was labelled as ineffective (No). | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03017846 -
Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
|
Phase 2 | |
Recruiting |
NCT05937672 -
Cold Atmospheric Plasma Device Extension Study
|
Phase 3 | |
Completed |
NCT04535531 -
A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
|
Phase 3 | |
Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
Withdrawn |
NCT05536882 -
MC RCT - BPO vs Adapalene
|
Phase 3 | |
Completed |
NCT03377790 -
Cantharidin Application in Molluscum Patients-1
|
Phase 3 | |
Completed |
NCT01348386 -
Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum
|
Phase 2/Phase 3 | |
Completed |
NCT05634460 -
Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum
|
Phase 1 | |
Completed |
NCT03186378 -
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
|
Phase 2 | |
Completed |
NCT03927716 -
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
|
Phase 3 | |
Recruiting |
NCT04476186 -
The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children
|
N/A | |
Completed |
NCT03927703 -
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
|
Phase 3 | |
Completed |
NCT02665260 -
Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
|
Phase 2 | |
Completed |
NCT03436615 -
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
|
Phase 2 | |
Recruiting |
NCT02759900 -
Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
|
N/A | |
Completed |
NCT05680181 -
Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
|
||
Completed |
NCT03077750 -
A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum
|
Phase 2 | |
Terminated |
NCT02024581 -
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum
|
Phase 2 | |
Completed |
NCT03377803 -
Cantharidin Application in Molluscum Patients
|
Phase 3 | |
Withdrawn |
NCT03336372 -
Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients
|
Early Phase 1 |